Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases

Nemica Thavarajah; Saurabh Ray; Gillian Bedard; Liying Zhang; David Cella; Erin Wong; Cyril Danjoux; May Tsao; Elizabeth Barnes; Arjun Sahgal; Hany Soliman; Natalie Pulenzas; Breanne Lechner; Edward Chow

doi:10.2217/cns.14.49

Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases

Nemica Thavarajah, Saurabh Ray, Gillian Bedard, Liying Zhang, David Cella, Erin Wong, Cyril Danjoux, May Tsao, Elizabeth Barnes, Arjun Sahgal, Hany Soliman, Natalie Pulenzas, Breanne Lechner, Edward Chow

Medical Social Sciences

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

OBJECTIVE: To test the reliability, clinical and psychometric validity of the Brain Symptom and Impact Questionnaire (BASIQ) in patients with brain metastases.

METHODS: Brain metastases patients were interviewed using the BASIQ, Functional Assessment of Cancer-Brain (FACT-Br) and FACT-General (FACT-G) at baseline, with a follow-up assessment at 1 month.

RESULTS: Forty patients had complete one data and the median age was 64 years. Patients with higher KPS, ECOG of 2, primary breast cancer, or >3 brain metastases, scored higher on the symptom scale of the BASIQ. All subscales showed no significant change in patient symptoms from baseline to follow-up.

CONCLUSION: This study supports that the reliability, clinical and psychometric validity of BASIQ to be used in brain metastases patients.

Original language	English (US)
Pages (from-to)	11-23
Number of pages	13
Journal	CNS oncology
Volume	4
Issue number	1
DOIs	https://doi.org/10.2217/cns.14.49
State	Published - Jan 1 2015

Keywords

BASIQ
brain metastases
field-testing
psychometric validation
quality of life
questionnaire

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/cns.14.49

Cite this

Thavarajah, N., Ray, S., Bedard, G., Zhang, L., Cella, D., Wong, E., Danjoux, C., Tsao, M., Barnes, E., Sahgal, A., Soliman, H., Pulenzas, N., Lechner, B., & Chow, E. (2015). Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases. CNS oncology, 4(1), 11-23. https://doi.org/10.2217/cns.14.49

@article{651404eb175244be9462132128b9d3dd,

title = "Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases",

abstract = "OBJECTIVE: To test the reliability, clinical and psychometric validity of the Brain Symptom and Impact Questionnaire (BASIQ) in patients with brain metastases.METHODS: Brain metastases patients were interviewed using the BASIQ, Functional Assessment of Cancer-Brain (FACT-Br) and FACT-General (FACT-G) at baseline, with a follow-up assessment at 1 month.RESULTS: Forty patients had complete one data and the median age was 64 years. Patients with higher KPS, ECOG of 2, primary breast cancer, or >3 brain metastases, scored higher on the symptom scale of the BASIQ. All subscales showed no significant change in patient symptoms from baseline to follow-up.CONCLUSION: This study supports that the reliability, clinical and psychometric validity of BASIQ to be used in brain metastases patients.",

keywords = "BASIQ, brain metastases, field-testing, psychometric validation, quality of life, questionnaire",

author = "Nemica Thavarajah and Saurabh Ray and Gillian Bedard and Liying Zhang and David Cella and Erin Wong and Cyril Danjoux and May Tsao and Elizabeth Barnes and Arjun Sahgal and Hany Soliman and Natalie Pulenzas and Breanne Lechner and Edward Chow",

year = "2015",

month = jan,

day = "1",

doi = "10.2217/cns.14.49",

language = "English (US)",

volume = "4",

pages = "11--23",

journal = "CNS oncology",

issn = "2045-0915",

publisher = "Future Medicine Ltd.",

number = "1",

}

Thavarajah, N, Ray, S, Bedard, G, Zhang, L, Cella, D, Wong, E, Danjoux, C, Tsao, M, Barnes, E, Sahgal, A, Soliman, H, Pulenzas, N, Lechner, B & Chow, E 2015, 'Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases', CNS oncology, vol. 4, no. 1, pp. 11-23. https://doi.org/10.2217/cns.14.49

TY - JOUR

T1 - Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases

AU - Thavarajah, Nemica

AU - Ray, Saurabh

AU - Bedard, Gillian

AU - Zhang, Liying

AU - Cella, David

AU - Wong, Erin

AU - Danjoux, Cyril

AU - Tsao, May

AU - Barnes, Elizabeth

AU - Sahgal, Arjun

AU - Soliman, Hany

AU - Pulenzas, Natalie

AU - Lechner, Breanne

AU - Chow, Edward

PY - 2015/1/1

Y1 - 2015/1/1

N2 - OBJECTIVE: To test the reliability, clinical and psychometric validity of the Brain Symptom and Impact Questionnaire (BASIQ) in patients with brain metastases.METHODS: Brain metastases patients were interviewed using the BASIQ, Functional Assessment of Cancer-Brain (FACT-Br) and FACT-General (FACT-G) at baseline, with a follow-up assessment at 1 month.RESULTS: Forty patients had complete one data and the median age was 64 years. Patients with higher KPS, ECOG of 2, primary breast cancer, or >3 brain metastases, scored higher on the symptom scale of the BASIQ. All subscales showed no significant change in patient symptoms from baseline to follow-up.CONCLUSION: This study supports that the reliability, clinical and psychometric validity of BASIQ to be used in brain metastases patients.

AB - OBJECTIVE: To test the reliability, clinical and psychometric validity of the Brain Symptom and Impact Questionnaire (BASIQ) in patients with brain metastases.METHODS: Brain metastases patients were interviewed using the BASIQ, Functional Assessment of Cancer-Brain (FACT-Br) and FACT-General (FACT-G) at baseline, with a follow-up assessment at 1 month.RESULTS: Forty patients had complete one data and the median age was 64 years. Patients with higher KPS, ECOG of 2, primary breast cancer, or >3 brain metastases, scored higher on the symptom scale of the BASIQ. All subscales showed no significant change in patient symptoms from baseline to follow-up.CONCLUSION: This study supports that the reliability, clinical and psychometric validity of BASIQ to be used in brain metastases patients.

KW - BASIQ

KW - brain metastases

KW - field-testing

KW - psychometric validation

KW - quality of life

KW - questionnaire

UR - http://www.scopus.com/inward/record.url?scp=84940740426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940740426&partnerID=8YFLogxK

U2 - 10.2217/cns.14.49

DO - 10.2217/cns.14.49

M3 - Article

C2 - 25586422

SN - 2045-0915

VL - 4

SP - 11

EP - 23

JO - CNS oncology

JF - CNS oncology

IS - 1

ER -

Psychometric validation of the Brain Symptom and Impact Questionnaire (BASIQ) version 1.0 to assess quality of life in patients with brain metastases

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this